Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287638 | 0.91 | LMNA (0.50) | KDM4EALDH1A1TDP1L3MBTL1KMT2A | |
| SCHEMBL4297009 | 0.88 | KDM4E (0.47) | KDM4EALDH1A1TDP1NPSR1KMT2A | |
| SCHEMBL4287502 | 0.87 | KDM4E (0.49) | KDM4EALDH1A1TDP1L3MBTL1NPSR1 | |
| SCHEMBL4282070 | 0.87 | NPC1 (0.48) | KDM4EALDH1A1L3MBTL1FFAR1KMT2A | |
| SCHEMBL4290228 | 0.86 | MAPT (0.51) | KDM4EALDH1A1L3MBTL1ALOX15KMT2A | |
| SCHEMBL4283481 | 0.86 | MEN1 (0.47) | KDM4EALDH1A1L3MBTL1KMT2AMEN1 | |
| SCHEMBL4289100 | 0.84 | KMT2A (0.54) | KDM4EALDH1A1NPSR1KMT2AMEN1 | |
| SCHEMBL3494366 | 0.84 | TEAD1 (0.50) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL4293729 | 0.83 | MAPK1 (0.41) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL4285550 | 0.83 | MEN1 (0.40) | KDM4EALDH1A1TDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4E 760/4885ALDH1A1 388/4885TDP1 2253/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4E 760/4885ALDH1A1 388/4885TDP1 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.